Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term outcomes of HIV-infected children in Thailand: the Thailand Pediatric HIV Observational Database.
Phongsamart W, Hansudewechakul R, Bunupuradah T, Klinbuayaem V, Teeraananchai S, Prasithsirikul W, Kerr SJ, Akarathum N, Denjunta S, Ananworanich J, Chokephaibulkit K. Phongsamart W, et al. Among authors: klinbuayaem v. Int J Infect Dis. 2014 May;22:19-24. doi: 10.1016/j.ijid.2013.12.011. Epub 2014 Feb 25. Int J Infect Dis. 2014. PMID: 24576843 Free article.
Risk of first-line antiretroviral therapy failure in HIV-infected Thai children and adolescents.
Bunupuradah T, Sricharoenchai S, Hansudewechakul R, Klinbuayaem V, Teeraananchai S, Wittawatmongkol O, Akarathum N, Prasithsirikul W, Ananworanich J; Pediatric PROGRESS Study Team. Bunupuradah T, et al. Among authors: klinbuayaem v. Pediatr Infect Dis J. 2015 Mar;34(3):e58-62. doi: 10.1097/INF.0000000000000584. Pediatr Infect Dis J. 2015. PMID: 25478649
Depression and anxiety were low amongst virally suppressed, long-term treated HIV-infected individuals enrolled in a public sector antiretroviral program in Thailand.
Prasithsirikul W, Chongthawonsatid S, Ohata PJ, Keadpudsa S, Klinbuayaem V, Rerksirikul P, Kerr SJ, Ruxrungtham K, Ananworanich J, Avihingsanon A; PROGRESS study team. Prasithsirikul W, et al. Among authors: klinbuayaem v. AIDS Care. 2017 Mar;29(3):299-305. doi: 10.1080/09540121.2016.1201194. Epub 2016 Aug 10. AIDS Care. 2017. PMID: 27683949
Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.
Cressey TR, Avihingsanon A, Halue G, Leenasirimakul P, Sukrakanchana PO, Tawon Y, Jaisieng N, Jourdain G, Podany AT, Fletcher CV, Klinbuayaem V, Bowonwatanuwong C. Cressey TR, et al. Among authors: klinbuayaem v. Clin Infect Dis. 2015 Aug 15;61(4):633-9. doi: 10.1093/cid/civ346. Epub 2015 Apr 28. Clin Infect Dis. 2015. PMID: 25921689 Free PMC article. Clinical Trial.
Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial.
Bunupuradah T, Kiertiburanakul S, Avihingsanon A, Chetchotisakd P, Techapornroong M, Leerattanapetch N, Kantipong P, Bowonwatanuwong C, Banchongkit S, Klinbuayaem V, Mekviwattanawong S, Nimitvilai S, Jirajariyavej S, Prasithsirikul W, Munsakul W, Bhakeecheep S, Chaivooth S, Phanuphak P, Cooper DA, Apornpong T, Kerr SJ, Emery S, Ruxrungtham K; LASA Study Group. Bunupuradah T, et al. Among authors: klinbuayaem v. Lancet HIV. 2016 Aug;3(8):e343-e350. doi: 10.1016/S2352-3018(16)30010-8. Epub 2016 May 24. Lancet HIV. 2016. PMID: 27470026 Clinical Trial.
Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.
Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Mocroft A, et al. PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar. PLoS Med. 2015. PMID: 25826420 Free PMC article.
A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
Bunupuradah T, Chetchotisakd P, Ananworanich J, Munsakul W, Jirajariyavej S, Kantipong P, Prasithsirikul W, Sungkanuparph S, Bowonwatanuwong C, Klinbuayaem V, Kerr SJ, Sophonphan J, Bhakeecheep S, Hirschel B, Ruxrungtham K; HIV STAR Study Group. Bunupuradah T, et al. Among authors: klinbuayaem v. Antivir Ther. 2012;17(7):1351-61. doi: 10.3851/IMP2443. Epub 2012 Jul 2. Antivir Ther. 2012. PMID: 23075703 Clinical Trial.
HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.
Bunupuradah T, Bowonwattanuwong C, Jirajariyavej S, Munsakul W, Klinbuayaem V, Sophonphan J, Mahanontharit A, Hirschel B, Ruxrungtham K, Ananworanich J; HIV STAR Study team. Bunupuradah T, et al. Among authors: klinbuayaem v. Antivir Ther. 2014;19(6):579-86. doi: 10.3851/IMP2737. Epub 2014 Jan 24. Antivir Ther. 2014. PMID: 24464590 Clinical Trial.
50 results